Takeda enters $255m lupus partnership with Resolve
This article was originally published in Scrip
Executive Summary
Takeda Pharmaceutical and Resolve Therapeutics have entered into a partnership to develop compounds for the treatment of Systemic Lupus Erythematosus (SLE) and other autoimmune diseases, announcing that the lead compound, RSLV-132, a nuclease Fc fusion protein, will begin clinical development later this year.